COMMUNIQUÉS West-GlobeNewswire

IHMA annonce une nouvelle entreprise en Inde pour renforcer son soutien mondial au développement de médicaments anti-infectieux pour l'industrie biopharmaceutique
01/11/2018
SCHAUMBURG, Illinois, 01 nov. 2018 (GLOBE NEWSWIRE) -- International Health Management Associates, Inc. / IHMA Europe Sàrl (IHMA), société mondiale qui propose des services de laboratoire et de consultation à l' [...]
Agile Therapeutics Reports Third Quarter 2018 Financial Results
01/11/2018
Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported [...]
Neon Therapeutics to Host Investor Event at Society for Immunotherapy of Cancer 33rd Annual Meeting
01/11/2018
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it will host an [...]
Adverum Biotechnologies Provides Program Updates
01/11/2018
Preliminary data from the ADVANCE Phase 1/2 Study in A1AT deficiency showed ADVM-043 in doses of up to 1.5 x 10 13 vg/kg were safely administered and well tolerated; Protein expression did not meet a clinically [...]
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018
01/11/2018
GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of U.S. financial markets on [...]
Pacific Biosciences of California, Inc. Announces Third Quarter 2018 Financial Results
01/11/2018
MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2018. Total revenue for the third [...]
WW Announces Strong Third Quarter 2018 Results
01/11/2018
Updates Full Year 2018 Earnings Guidance End of Period Subscribers in Q3 2018 up 25% year-over-year to 4.2 million Total Paid Weeks in Q3 2018 up 24% year-over-year Revenues in Q3 2018 of $366 million, up 13%, or 14% on [...]
VIVUS Reports Third Quarter 2018 Financial Results
01/11/2018
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and [...]
Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
01/11/2018
BURLINGAME, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted [...]
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
01/11/2018
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage [...]
Equillium to Present at Investor Conferences in November 2018
01/11/2018
LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory [...]
Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference
01/11/2018
WEST CHESTER, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical [...]
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
01/11/2018
-Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation of etigilimab data at Society for [...]
Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
01/11/2018
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored [...]
Fluidigm Announces Third Quarter 2018 Financial Results
01/11/2018
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation [...]
Dova Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 8, 2018
01/11/2018
DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Thursday, November 8, 2018 at 4:30 p.m. ET to discuss third quarter 2018 financial results and [...]
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01/11/2018
BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]
Teladoc Health Announces Third Quarter 2018 Financial Results
01/11/2018
Third quarter revenue grows 62 percent year over year to $111.0 million Total paid membership grows 18 percent year over year to 22.6 million Third quarter total visits grow 110 percent year over year to 641,000 [...]
Sol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo
01/11/2018
NESS ZIONA, Israel, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing [...]

Pages